Investigational drug · Phase 2
GIM122
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GIM122"
First trial start
2023
Dec 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GIM122", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "GIM122" as an intervention, largest first.
Georgiamune IncIndustry
NCT06028074 · 111 participants (planned) · Start Dec 12, 2023 · Primary completion Sep 2026
Drug: GIM122 · For: Advanced Solid Malignancies
Sites: Los Angeles, California; San Francisco, California; Sarasota, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Malignancies
- PalacaparibAZD9574Phase 25 trials
AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- BMS-986523Phase 21 trial
Bristol Myers Squibb · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- BMS-986548Phase 21 trial
Bristol Myers Squibb · Advanced Solid Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.